Dapagliflozin (dapagliflozin)
Dapagliflozin is a sglt2 inhibitor (sodium-glucose co-transporter 2 inhibitor) from AstraZeneca (originally developed with Bristol-Myers Squibb), marketed originally as Forxiga. This monograph covers approved indications, mechanism, dosing, side effects, the generic manufacturer landscape and verified list prices.
How much does dapagliflozin cost?
8 manufacturers produce generic dapagliflozin 5 mg in Bangladesh, with list unit prices from BDT 10 to BDT 20 (US$0.08–US$0.16); a 30-unit month costs about US$2.44–US$4.88. The cheapest listed brand is Dapatab (The IBN SINA Pharmaceutical PLC).
Source: MedEx Bangladesh registry (DGDA-registered brands), updated September 2026. Prices move with FX, pack size and pharmacy margin — confirm current stock and price with a licensed importer.
Overview
Dapagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor marketed by AstraZeneca as Forxiga in the EU, UK, Asia and Southeast Asia, Farxiga in the United States, and 安达唐 in China. It was originally developed with Bristol-Myers Squibb. It is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, and since June 2024 also in children aged 10 years and older in the United States. Beyond glucose lowering, the label has expanded to three outcome-based indications: reducing the risk of hospitalisation for heart failure in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors; reducing the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults with heart failure regardless of ejection fraction (2023 US label); and reducing sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease at risk of progression. The agreed dose is 10 mg once daily for the heart failure and kidney indications and for heart failure risk reduction in type 2 diabetes; glycaemic control starts at 5 mg once daily and may be increased to 10 mg. It is not for type 1 diabetes and is not recommended for glucose lowering when eGFR is below 45 mL/min/1.73 m2, although patients already taking it may continue at 10 mg once daily at lower eGFR levels to reduce eGFR decline and cardiovascular events. Dapagliflozin is off patent in many markets. Bangladeshi manufacturers including Incepta, ACI, Beacon, Concord, Opsonin, IBN SINA and Jenphar list 5 mg and 10 mg tablets at BDT 10-30 per tablet, against an Indian originator pack price of INR 536-566; Indian generics such as Sun's Oxra are listed at INR 162-223.
Dapagliflozin price list — Bangladesh
Every DGDA-registered brand of this molecule with its list unit price, including the originator for comparison. Bangladesh is the most transparent reference market for on-patent generics.
| Brand | Manufacturer | Strength | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Dapatab Lowest | The IBN SINA Pharmaceutical PLC | 5 mg Tablet | BDT 10 | US$0.08 | 3 x 10: ৳ 300.00 |
| Dapaglip | Incepta Pharmaceuticals Ltd. | 5 mg Tablet | BDT 16 | US$0.13 | 3 x 10: ৳ 480.00 |
| Daparol | Drug International Ltd. | 5 mg Tablet | BDT 16 | US$0.13 | 1 x 14: ৳ 224.00 |
| Dapawin | Beacon Pharmaceuticals PLC | 5 mg Tablet | BDT 16 | US$0.13 | 3 x 10: ৳ 480.00 |
| Diadap | Opsonin Pharma Ltd. | 5 mg Tablet | BDT 16 | US$0.13 | 3 x 10: ৳ 480.00 |
| Dialozin | Jenphar Bangladesh Ltd. | 5 mg Tablet | BDT 16 | US$0.13 | 3 x 10: ৳ 480.00 |
| Dapazin | Concord Pharmaceuticals Ltd. | 5 mg Tablet | BDT 20 | US$0.16 | 2 x 14: ৳ 560.00 |
| Glycema | ACI Limited | 5 mg Tablet | BDT 20 | US$0.16 | 3 x 10: ৳ 600.00 |
| Dapaglip | Incepta Pharmaceuticals Ltd. | 10 mg Tablet | BDT 30 | US$0.24 | 2 x 10: ৳ 600.00 |
| Dapazin | Concord Pharmaceuticals Ltd. | 10 mg Tablet | BDT 30 | US$0.24 | 1 x 14: ৳ 420.00 |
| Glycema | ACI Limited | 10 mg Tablet | BDT 30 | US$0.24 | 2 x 10: ৳ 600.00 |
Source: MedEx Bangladesh drug registry (list prices of DGDA-registered brands). Unit prices move with pack size, pharmacy and exchange rate — reference only. Original registry page
How it works
Dapagliflozin blocks a protein in the kidney called SGLT2, which normally pulls glucose back out of the urine into the blood. With that protein blocked, more glucose leaves the body in the urine, so blood sugar goes down. It works without depending on insulin, and it also makes the kidney pass more salt and water, which reduces the workload on the heart and kidneys.
Reversible, highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2) in the S1/S2 segments of the renal proximal convoluted tubule. Inhibition reduces renal glucose reabsorption, increases urinary glucose excretion and produces osmotic diuresis, lowering HbA1c independently of insulin secretion or sensitivity. Concomitant natriuresis, reduced glomerular hyperfiltration, lower arterial stiffness and a shift toward ketone-body myocardial substrate use are the proposed mechanisms behind the heart failure and chronic kidney disease benefits.
Approved indications
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- To improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes mellitus (US, June 2024)
- To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors
- To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure (any ejection fraction as of the 2023 US label)
- To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression
- Not for type 1 diabetes; not recommended for glycemic control when eGFR is less than 45 mL/min/1.73 m2; not expected to work in polycystic kidney disease
Dosage & administration
Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food.
Dose adjustment
US label dosing by eGFR: eGFR 45 or greater - 5-10 mg once daily as above; eGFR 25 to less than 45 - 10 mg once daily; eGFR less than 25 - initiation not recommended, but patients already on it may continue 10 mg once daily to reduce eGFR decline, ESKD, CV death and hospitalization for heart failure. Assess renal function and volume status before and during therapy and correct volume depletion first. Mild, moderate or severe hepatic impairment: no dose adjustment in the US label (the UK SmPC recommends a 5 mg starting dose in severe hepatic impairment). No dose adjustment based on age. Not recommended with dialysis.
Side effects
Female genital mycotic (yeast) infections - the most common reaction (5% or greater) · Urinary tract infection · Nasopharyngitis (stuffy or runny nose, sore throat) · Polyuria, increased urination, thirst, nocturia · Volume depletion - dizziness, hypotension (higher risk in elderly, renal impairment, loop diuretic users) · Necrotizing fasciitis of the perineum (Fournier's gangrene) - rare, life-threatening · Hypoglycemia when combined with insulin or an insulin secretagogue
- Diabetic ketoacidosis - rare but can occur with normal or only mildly raised blood glucose
- Urosepsis and pyelonephritis
Monitoring
- Renal function (eGFR) before initiation and then as clinically indicated
- Volume status, blood pressure and symptoms of hypotension, especially in the elderly, renal impairment, low systolic BP, or diuretic use
- Blood glucose and HbA1c (reassess around 3 months)
- Ketones and acid-base status if the patient is unwell, dehydrated, fasting, post-surgery, or on a very-low-carbohydrate diet
- Signs and symptoms of urinary tract and genital mycotic infections
- Signs of hypoglycemia if on insulin or a sulfonylurea (consider lowering their dose)
Generic and biosimilar landscape
Farxiga (US) and Forxiga (ex-US) are the reference products. FDA-approved generic dapagliflozin tablets (including the first approvals for the heart-failure risk indication in type 2 diabetes) were licensed through ANDAs on evidence of pharmaceutical equivalence and bioequivalence in the same 5 mg and 10 mg strengths, and are considered therapeutically equivalent. Country-level generics should be checked against the locally registered reference product and the local regulator (CDSCO in India, DGDA in Bangladesh, NPRA in Malaysia, BPOM in Indonesia, FDA Philippines).
Who makes it
| Manufacturer | Country | Brand | Strength | Notes |
|---|---|---|---|---|
| Incepta Pharmaceuticals Ltd. | Bangladesh | Dapaglip | 5 mg, 10 mg | Both strengths listed with prices on MedEx |
| ACI Limited | Bangladesh | Glycema | 5 mg, 10 mg | Listed on MedEx |
| Concord Pharmaceuticals Ltd. | Bangladesh | Dapazin | 5 mg, 10 mg | Listed on MedEx |
| Beacon Pharmaceuticals PLC | Bangladesh | Dapawin | 5 mg | Listed on MedEx |
| Drug International Ltd. | Bangladesh | Daparol | 5 mg | Listed on MedEx |
| The IBN SINA Pharmaceutical PLC | Bangladesh | Dapatab | 5 mg | Lowest-priced local brand found on MedEx |
| Opsonin Pharma Ltd. | Bangladesh | Diadap | 5 mg | Listed on MedEx |
| Jenphar Bangladesh Ltd. | Bangladesh | Dialozin | 5 mg | Listed on MedEx |
| Sun Pharmaceutical Industries Ltd. | India | Oxra | 5 mg, 10 mg | Listed on 1mg with prices |
| Natco Pharma | India | Dapnat | 10 mg | Launched in India as a generic version of Forxiga (dapagliflozin) |
| Cipla Ltd. | India | No Cipla dapagliflozin brand confirmed from the sources reviewed in this pass - verify on the Cipla product list before publishing |
Availability in Southeast Asia
| Country | Status | Notes |
|---|---|---|
| Bangladesh | Available - multiple locally manufactured generics (Incepta, ACI, Beacon, Drug International, Concord, Opsonin, IBN SINA, Jenphar) | MedEx lists 11 brand/strength entries; local generics cost roughly BDT 10-30 per tablet versus BDT 69 per tablet for imported Jardiance-class pricing |
| Philippines | Approved and marketed (Forxiga) | Forxiga has a full MIMS Philippines monograph including dosage and indications; FDA Philippines registration not re-verified in this pass |
| Indonesia | Approved and marketed (Forxiga) | Forxiga listed with full product information in MIMS Indonesia |
| Malaysia | Not verified in this pass | No direct Forxiga Malaysia source captured; check NPRA Quest3+ product search before publishing |
| Vietnam | Not verified in this pass | Check DAV (Drug Administration of Vietnam) registration database |
| Thailand | Not verified in this pass | Check Thai FDA registration database |
Price by country
Reference prices by market
| Market | Product | Listed price | Source |
|---|---|---|---|
| Bangladesh | Dapaglip 5 mg tablet (Incepta) | BDT 16.00 per tablet; pack 3 x 10 = BDT 480 | medex.com.bd |
| Bangladesh | Dapaglip 10 mg tablet (Incepta) | BDT 30.00 per tablet; pack 2 x 10 = BDT 600 | medex.com.bd |
| Bangladesh | Dapatab 5 mg tablet (IBN SINA) | BDT 10.00 per tablet; pack 3 x 10 = BDT 300 | medex.com.bd |
| India | Forxiga (AstraZeneca, originator) | INR 536 to INR 566 per pack | 1mg.com |
| India | Oxra (Sun Pharmaceutical Industries Ltd.) | INR 162 to INR 223 per pack | 1mg.com |
| India | Dapasidh (Sidhbali Formulations) | INR 112 to INR 168 per pack | 1mg.com |
Frequently asked questions
What is dapagliflozin used for besides type 2 diabetes?
Dapagliflozin is approved for: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; To improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes mellitus (US, June 2024); To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors; To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure (any ejection fraction as of the 2023 US label); To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. It is a dapagliflozin (SGLT2 inhibitor), originally marketed as Forxiga (EU/UK/Asia/SEA); Farxiga (US); 安达唐 (China); 安達糖 (Taiwan) by AstraZeneca (originally developed with Bristol-Myers Squibb).
Is Forxiga the same as Farxiga?
Farxiga (US) and Forxiga (ex-US) are the reference products. FDA-approved generic dapagliflozin tablets (including the first approvals for the heart-failure risk indication in type 2 diabetes) were licensed through ANDAs on evidence of pharmaceutical equivalence and bioequivalence in the same 5 mg and 10 mg strengths, and are considered therapeutically equivalent. Country-level generics should be checked against the locally registered reference product and the local regulator (CDSCO in India, DGDA in Bangladesh, NPRA in Malaysia, BPOM in Indonesia, FDA Philippines). Manufacturers supplying dapagliflozin generic versions include ACI Limited, Beacon Pharmaceuticals PLC, Cipla Ltd., Concord Pharmaceuticals Ltd., Drug International Ltd., Incepta Pharmaceuticals Ltd., Jenphar Bangladesh Ltd., Natco Pharma. Brands registered in Bangladesh include Dapaglip, Daparol, Dapatab, Dapawin, Dapazin, Diadap.
What is the usual dose of dapagliflozin for heart failure?
Standard dosing for dapagliflozin: Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food. Dose adjustments: US label dosing by eGFR: eGFR 45 or greater - 5-10 mg once daily as above; eGFR 25 to less than 45 - 10 mg once daily; eGFR less than 25 - initiation not recommended, but patients already on it may continue 10 mg once daily to reduce eGFR decline, ESKD, CV death and hospitalization for heart failure. Assess renal function and volume status before and during therapy and correct volume depletion first. Mild, moderate or severe hepatic impairment: no dose adjustment in the US label (the UK SmPC recommends a 5 mg starting dose in severe hepatic impairment). No dose adjustment based on age. Not recommended with dialysis.
Do I need a dose change if my kidney function is reduced (low eGFR)?
Standard dosing for dapagliflozin: Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food. Dose adjustments: US label dosing by eGFR: eGFR 45 or greater - 5-10 mg once daily as above; eGFR 25 to less than 45 - 10 mg once daily; eGFR less than 25 - initiation not recommended, but patients already on it may continue 10 mg once daily to reduce eGFR decline, ESKD, CV death and hospitalization for heart failure. Assess renal function and volume status before and during therapy and correct volume depletion first. Mild, moderate or severe hepatic impairment: no dose adjustment in the US label (the UK SmPC recommends a 5 mg starting dose in severe hepatic impairment). No dose adjustment based on age. Not recommended with dialysis.
Does dapagliflozin cause weight loss?
Dapagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Forxiga (EU/UK/Asia/SEA); Farxiga (US); 安达唐 (China); 安達糖 (Taiwan) by AstraZeneca (originally developed with Bristol-Myers Squibb)) Dapagliflozin blocks a protein in the kidney called SGLT2, which normally pulls glucose back out of the urine into the blood. With that protein blocked, more glucose leaves the body in the urine, so blood sugar goes down. It works without depending on insulin, and it also makes the kidney pass more salt and water, which reduces the workload on the heart and kidneys. Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food.
Can dapagliflozin cause a urinary tract infection or a yeast infection?
Dapagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Forxiga (EU/UK/Asia/SEA); Farxiga (US); 安达唐 (China); 安達糖 (Taiwan) by AstraZeneca (originally developed with Bristol-Myers Squibb)) Dapagliflozin blocks a protein in the kidney called SGLT2, which normally pulls glucose back out of the urine into the blood. With that protein blocked, more glucose leaves the body in the urine, so blood sugar goes down. It works without depending on insulin, and it also makes the kidney pass more salt and water, which reduces the workload on the heart and kidneys. Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food.
Can I take dapagliflozin if I have type 1 diabetes?
Dapagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Forxiga (EU/UK/Asia/SEA); Farxiga (US); 安达唐 (China); 安達糖 (Taiwan) by AstraZeneca (originally developed with Bristol-Myers Squibb)) Dapagliflozin blocks a protein in the kidney called SGLT2, which normally pulls glucose back out of the urine into the blood. With that protein blocked, more glucose leaves the body in the urine, so blood sugar goes down. It works without depending on insulin, and it also makes the kidney pass more salt and water, which reduces the workload on the heart and kidneys. Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food.
Is generic dapagliflozin as effective as Forxiga?
Farxiga (US) and Forxiga (ex-US) are the reference products. FDA-approved generic dapagliflozin tablets (including the first approvals for the heart-failure risk indication in type 2 diabetes) were licensed through ANDAs on evidence of pharmaceutical equivalence and bioequivalence in the same 5 mg and 10 mg strengths, and are considered therapeutically equivalent. Country-level generics should be checked against the locally registered reference product and the local regulator (CDSCO in India, DGDA in Bangladesh, NPRA in Malaysia, BPOM in Indonesia, FDA Philippines). Manufacturers supplying dapagliflozin generic versions include ACI Limited, Beacon Pharmaceuticals PLC, Cipla Ltd., Concord Pharmaceuticals Ltd., Drug International Ltd., Incepta Pharmaceuticals Ltd., Jenphar Bangladesh Ltd., Natco Pharma. Brands registered in Bangladesh include Dapaglip, Daparol, Dapatab, Dapawin, Dapazin, Diadap.
What happens if I stop taking dapagliflozin suddenly?
Dapagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Forxiga (EU/UK/Asia/SEA); Farxiga (US); 安达唐 (China); 安達糖 (Taiwan) by AstraZeneca (originally developed with Bristol-Myers Squibb)) Dapagliflozin blocks a protein in the kidney called SGLT2, which normally pulls glucose back out of the urine into the blood. With that protein blocked, more glucose leaves the body in the urine, so blood sugar goes down. It works without depending on insulin, and it also makes the kidney pass more salt and water, which reduces the workload on the heart and kidneys. Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food.
Should I stop dapagliflozin before surgery?
Dapagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Forxiga (EU/UK/Asia/SEA); Farxiga (US); 安达唐 (China); 安達糖 (Taiwan) by AstraZeneca (originally developed with Bristol-Myers Squibb)) Dapagliflozin blocks a protein in the kidney called SGLT2, which normally pulls glucose back out of the urine into the blood. With that protein blocked, more glucose leaves the body in the urine, so blood sugar goes down. It works without depending on insulin, and it also makes the kidney pass more salt and water, which reduces the workload on the heart and kidneys. Glycemic control: start 5 mg orally once daily, may be increased to 10 mg once daily for additional glycemic control. All other indications (heart failure, chronic kidney disease, heart-failure risk in type 2 diabetes): 10 mg once daily, at any time of day, with or without food.
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202293s035lbl.pdf
- https://www.astrazeneca.com/content/az-us/media/press-releases/2023/farxiga-extended-in-the-us-to-reduce-risk-of-cardiovascular-death-and-hospitalization-for-heart-failure-to-a-broader-range-of-patients-05092023.html
- https://www.drugs.com/history/farxiga.html
- https://medex.com.bd/generics/339/dapagliflozin-propanediol/brand-names
- https://medex.com.bd/brands/30843/dapaglip-10-mg-tablet
- https://www.1mg.com/generics/dapagliflozin-212959
- https://www.mims.com/philippines/drug/info/forxiga/dosage
- https://www.mims.com/indonesia/drug/info/forxiga?type=full
- https://www.medicines.org.uk/emc/product/7607/smpc
- https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/forxiga-product-monograph-en.pdf
- https://www.expresspharma.in/dapnat-launch-to-boost-natcos-presence-in-indias-diabetes-market-but-concerted-efforts-required-says-globaldata
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Related molecules in the same therapeutic area
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.